NEW YORK (GenomeWeb News) – Pressure BioSciences said in a regulatory document on Tuesday that it has entered into a securities purchase agreement, raising a little more than $1.2 million.

Pressure Bio entered into the agreement on Jan. 29 with various accredited investors to sell them an aggregate of 4,875 units at $250 per unit, the company said in a document filed with the US Securities and Exchange Commission. Purchasers included existing and new investors in the company and members of its board.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.